• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Nuwellis

Nuwellis, DaVita partner on ultrafiltration therapy pilot program

June 20, 2023 By Sean Whooley

Nuwellis (Nasdaq:NUWE) announced today that it entered into a supply and collaboration agreement with DaVita (NYSE:DVA). The agreement enables Nuwellis — formerly CHF Solutions — to pilot its Aquadex ultrafiltration therapy within selected U.S. markets. Aquadex, which removes excess fluid from patients suffering from hypervolemia (fluid overload), treats congestive heart failure and related conditions. DaVita […]

Filed Under: Blood Management, Business/Financial News, Cardiovascular, Featured, News Well, Vascular Tagged With: DaVita Inc., Nuwellis

SeaStar Medical, Nuwellis partner on kidney injury treatment

December 29, 2022 By Sean Whooley

SeaStar Medical (Nasdaq:ICU) and Nuwellis (Nasdaq:NUWE) today announced an exclusive U.S. license and distribution agreement. Nuwellis agreed to market and distribute SeaStar’s selective cytopheretic device (SCD). The SCD treats acute kidney injury (AKI) in children. It selectively targets the most activated pro-inflammatory neutrophils and monocytes to stop cytokine storm. The system works with continuous kidney […]

Filed Under: Blood Management, Business/Financial News, Pediatrics Tagged With: Nuwellis, SeaStar Medical

Nuwellis announces compliance with Nasdaq listing requirements

December 28, 2022 By Sean Whooley

Nuwellis (Nasdaq:NUWE) announced that it received notice from the Nasdaq market that it regained compliance with certain requirements. Minneapolis-based Nuwellis last month received a 180-day extension from Nasdaq to regain compliance. That followed a 180-day period in which the company failed to do so. Nasdaq granted the company time until May 29, 2023, to get […]

Filed Under: Blood Management, Business/Financial News, Cardiovascular, News Well, Wall Street Beat Tagged With: Nuwellis

Nuwellis can’t get a quorum for shareholder vote

December 8, 2022 By Sean Whooley

Nuwellis (Nasdaq:NUWE) announced today that it convened and adjourned its meeting of stockholders due to a failure to reach a quorum. The fluid overload treatment developer held the meeting on Dec. 7 without any business conducted due to the lack of quorum. Minneapolis-based Nuwellis develops the Aquadex SmartFlow system for ultrafiltration therapy. The company describes […]

Filed Under: Blood Management, Business/Financial News, Wall Street Beat Tagged With: Nuwellis

Nasdaq grants Nuwellis 180-day extension to comply with listing requirement

November 30, 2022 By Sean Whooley

Nuwellis (Nasdaq:NUWE) announced today that the Nasdaq market granted it a 180-day extension to regain compliance. Minneapolis-based Nuwellis must comply with the market’s minimum $1 bid price requirement for continued listing. The extension of 180 calendar days follows the expiration of its initial 180-day period to regain compliance on Nov. 28. As a result, Nuwellis […]

Filed Under: Blood Management, Business/Financial News, Wall Street Beat Tagged With: CHF Solutions Inc., Nuwellis

Nuwellis appoints new CFO following $11M public offering

October 19, 2022 By Danielle Kirsh

Nuwellis (Nasdaq:NUWE) today announced it appointed Lynn Blake as chief financial officer on news that it closed an $11 million underwritten public offering. Blake’s appointment is effective immediately. She brings more than two decades of senior financial leadership to the Minneapolis-based company. “Nuwellis is entering our next phase of commercial development with significant new opportunities in […]

Filed Under: Blood Management, Business/Financial News, News Well Tagged With: Nuwellis

Nuwellis prices $9.6M upsized offering

October 14, 2022 By Sean Whooley

Nuwellis (Nasdaq:NUWE) announced today that it priced an underwritten public offering worth approximately $9.6 million. The Minneapolis-based fluid overload treatment developer formerly operated as CHF Solutions. Nuwellis is offering preferred stock, common stock and warrants. It expects gross proceeds to total $9.6 million before deducting discounts, commissions and offering expenses, according to a news release. […]

Filed Under: Blood Management, Business/Financial News, Funding Roundup, News Well Tagged With: CHF Solutions Inc., Nuwellis

Nuwellis posts Q2 sales beat

August 9, 2022 By Sean Whooley

Nuwellis (Nasdaq:NUWE) shares were down today on second-quarter results that beat the consensus revenue forecast. The Minneapolis-based fluid overload treatment developer — formerly known as CHF Solutions — posted losses of $4.3 million, or 41¢ per share, on sales of $2.2 million for the three months ended June 30, 2022, for a slight bottom-line gain […]

Filed Under: Blood Management, Business/Financial News, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Nuwellis

Nuwellis rises on Street-beating Q1

May 10, 2022 By Sean Whooley

Nuwellis (Nasdaq:NUWE) shares ticked up today on first-quarter results that topped the consensus forecast. The Minneapolis-based fluid overload treatment developer — formerly known as CHF Solutions — posted losses of $4.5 million, or 42¢ per share, on sales of more than $1.9 million for the three months ended March 31, 2022, for a bottom-line from […]

Filed Under: Blood Management, Business/Financial News, Featured, MassDevice Earnings Roundup, Vascular, Wall Street Beat Tagged With: Nuwellis

Nuwellis posts mixed bag Q4

March 1, 2022 By Sean Whooley

Nuwellis (NSDQ:NUWE) shares were up today on fourth-quarter results that were mixed compared to the consensus forecast. The Minneapolis-based fluid overload treatment developer — formerly known as CHF Solutions — posted losses of $4.4 million, or 41¢ per share, on sales of $1.6 million for the three months ended Dec. 31, 2021, for a bottom-line […]

Filed Under: Blood Management, Business/Financial News, Cardiovascular, MassDevice Earnings Roundup, Wall Street Beat Tagged With: CHF Solutions Inc., Nuwellis

Nuwellis wins CE mark for 24-hour blood circuit set for use with Aquadex SmartFlow

September 21, 2021 By Sean Whooley

Nuwellis (NSDQ:NUWE) announced today that it received CE mark approval for its 24-hour blood circuit set for use with the Aquadex SmartFlow. Eden Prairie, Minnesota-based Nuwellis — formerly CHF Solutions — can now market the 24-hour blood circuit set (UF 500-24 Hour) in the European Union and other locations that recognize the CE mark. According […]

Filed Under: Blood Management, Cardiovascular, Featured, Pediatrics, Regulatory/Compliance Tagged With: CE Mark, CHF Solutions Inc., Nuwellis

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy